Cargando…

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia

PURPOSE: Decitabine, a DNA hypomethylating agent, was recently approved for use in Korea for older adults with acute myeloid leukemia (AML) who are not candidates for standard chemotherapy. This study aimed to evaluate the role of decitabine as a first-line treatment for older adults with AML. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyunsung, Chung, Haerim, Lee, Jungyeon, Jang, Jieun, Kim, Yundeok, Kim, Soo Jeong, Kim, Jin Seok, Min, Yoo Hong, Cheong, June-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122650/ https://www.ncbi.nlm.nih.gov/pubmed/27873493 http://dx.doi.org/10.3349/ymj.2017.58.1.35

Ejemplares similares

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience
por: Lee, Jung Yeon, et al.
Publicado: (2017)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant
por: Kim, Yundeok, et al.
Publicado: (2012)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
por: Labrador, Jorge, et al.
Publicado: (2022)

Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells
por: Kim, Soo-Jeong, et al.
Publicado: (2012)

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2017)

ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
por: Hwang, Doh Yu, et al.
Publicado: (2020)

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
por: Kim, Yundeok, et al.
Publicado: (2020)

Immunosuppressive role of CD11b(+)CD33(+)HLA‐DR(−) myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
por: Hyun, Shin Young, et al.
Publicado: (2020)

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
por: Yi, Jun Ho, et al.
Publicado: (2018)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin’s lymphoma
por: Kim, Yu Ri, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
por: Li, Jianyong, et al.
Publicado: (2015)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
por: Zhu, Jun-Feng, et al.
Publicado: (2022)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation
por: Jang, Ji Eun, et al.
Publicado: (2023)

Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness
por: Jacob, Linu A., et al.
Publicado: (2015)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

HBsAg-Negative, Anti-HBc–Negative Patients Still Have a Risk of Hepatitis B Virus–Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma
por: Park, Hyunsung, et al.
Publicado: (2018)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Kim, Jin Seok, et al.
Publicado: (2011)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
por: Park, Yumi, et al.
Publicado: (2018)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
por: Cho, Hyunsoo, et al.
Publicado: (2021)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance
por: CHEONG, JUNE-WON, et al.
Publicado: (2016)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells
por: Jang, Ji Eun, et al.
Publicado: (2020)

Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients
por: Kim, Yundeok, et al.
Publicado: (2013)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia
por: Dou, Liping, et al.
Publicado: (2019)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells
por: Li, Lanzhu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1fvh7ftv8phf6fhcneth7sb341